Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Instagram Outage Disrupts Thousands of U.S. Users 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
EMERYVILLE, Calif., March 04, 2016 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2015 after the market close, and will host a corporate update conference call and webcast on Thursday, March 10th at 4:30 PM Eastern Time.
| Thursday, March 10th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 888-337-8198 |
| International: | 719-325-2308 |
| Conference ID: | 5464024 |
| Webcast: | http://public.viavid.com/index.php?id=118497 |
| Replays, available through March 24, 2016: | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 5464024 |
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is an innovative pharmaceutical company committed to providing unique therapeutic solutions for people living with rare and burdensome disease conditions. Our focused strategy centers on advancing late-stage, high-value products for CNS disorders that will significantly improve outcomes for patients and physicians.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
